​
​

Vivos Therapeutics Ownership 2024 | Who Owns Vivos Therapeutics Now?

OverviewRevenueFinancialsChartTranscripts

Institutional Ownership

0.33%

Insider Ownership

5.93%

Retail Ownership

93.73%

Institutional Holders

1.00

Vivos Therapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RONALD BLUE TRUST, INC.----4,000-100.00%-Mar 31, 2024

Vivos Therapeutics's largest institutional shareholder is RONALD BLUE TRUST, INC., holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RONALD BLUE TRUST, INC.----4,000-100.00%-Mar 31, 2024

The largest Vivos Therapeutics shareholder by % of total assets is RONALD BLUE TRUST, INC.. The company owns 0.00 shares of Vivos Therapeutics (VVOS), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RONALD BLUE TRUST, INC.----4,000-100.00%-Mar 31, 2024

As of Mar 31 2024, Vivos Therapeutics's largest institutional buyer is RONALD BLUE TRUST, INC.. The company purchased -4.00K stocks of VVOS, valued at -.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RONALD BLUE TRUST, INC.----4,000-100.00%-Mar 31, 2024

As of Mar 31 2024, Vivos Therapeutics's biggest institutional seller is RONALD BLUE TRUST, INC.. The company sold -4.00K shares of VVOS, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RONALD BLUE TRUST, INC.----4,000-100.00%-Mar 31, 2024

Vivos Therapeutics's largest sold out institutional shareholder by shares sold is RONALD BLUE TRUST, INC., sold -4.00K shares, valued at -, as of undefined.

Vivos Therapeutics Mutual Fund Holders

Name% Total AssetsTotal SharesChange AmountChange %Date
ROYCE FUND0.05%348,000--Mar 31, 2024
VANGUARD VALLEY FORGE FUNDS0.01%5,061--Mar 31, 2024
VANGUARD INDEX FUNDS0.00%632,407--Mar 31, 2024
FIDELITY CONCORD STREET TRUST0.00%190,049--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%19,268--Mar 31, 2024
RUSSELL INVESTMENT CO0.00%178,485--Jan 31, 2024
RUSSELL INVESTMENT FUNDS0.00%28,109--Mar 31, 2024
SCHWAB CAPITAL TRUST0.00%9,382--Feb 29, 2024
FLEXSHARES TRUST0.00%9,264--Jan 31, 2024
Advisors' Inner Circle Fund III0.00%10,723--Jan 31, 2024
FIDELITY CONCORD STREET TRUST0.00%8,8105,600174.45%Feb 29, 2024
VANGUARD INDEX FUNDS0.00%10,579-10,579-50.00%Mar 31, 2024
USAA MUTUAL FUNDS TRUST0.00%2,036--Jan 31, 2024
EQ ADVISORS TRUST0.00%3,409--Mar 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%1,675--Mar 31, 2024
iSHARES TRUST0.00%2,580--Mar 31, 2024

Vivos Therapeutics's largest mutual fund holder by % of total assets is "ROYCE FUND", owning 348.00K shares, compromising 0.05% of its total assets.

Vivos Therapeutics Institutional Ownership Trends

Institutional Holdings Trend

DateHoldingsChange %
31 Dec, 231-96.15%
30 Sep, 2326-13.33%
30 Jun, 2330-3.23%
31 Mar, 233114.81%
31 Dec, 2227-
30 Sep, 22278.00%
30 Jun, 2225-13.79%
31 Mar, 2229-
31 Dec, 2129-34.09%
30 Sep, 214457.14%
30 Jun, 212864.71%
31 Mar, 211770.00%
31 Dec, 2010-

As of 31 Dec 23, 1 institutions are holding Vivos Therapeutics's shares, representing a decrease of -96.15% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Dec, 234,000-99.91%
30 Sep, 234,475,024-4.63%
30 Jun, 234,692,243-6.39%
31 Mar, 235,012,314220.31%
31 Dec, 221,564,827-26.28%
30 Sep, 222,122,576-2.66%
30 Jun, 222,180,477-12.28%
31 Mar, 222,485,61911.28%
31 Dec, 212,233,704-1.32%
30 Sep, 212,263,679-3.56%
30 Jun, 212,347,130186.00%
31 Mar, 21820,68412.44%
31 Dec, 20729,879-

Vivos Therapeutics (VVOS) has 4.00K shares outstanding as of 31 Dec 23, down -99.91% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Dec, 230.33%0.15%
30 Sep, 2314.95%4.16%
30 Jun, 2318.95%4.62%
31 Mar, 2320.24%43.77%
31 Dec, 226.80%6.80%
30 Sep, 2210.00%9.48%
30 Jun, 2210.27%7.49%
31 Mar, 2211.71%10.18%
31 Dec, 2110.73%9.08%
30 Sep, 2110.87%8.48%
30 Jun, 2111.32%55.73%
31 Mar, 214.51%25.91%
31 Dec, 204.17%-

As of 31 Dec 23, Vivos Therapeutics is held by 0.33% institutional shareholders, representing a 0.15% growth compared to 30 Sep 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Dec, 23--100.00%
30 Sep, 236-45.45%
30 Jun, 2311-15.38%
31 Mar, 23138.33%
31 Dec, 221250.00%
30 Sep, 228-20.00%
30 Jun, 2210-44.44%
31 Mar, 221863.64%
31 Dec, 2111-62.07%
30 Sep, 212926.09%
30 Jun, 212364.29%
31 Mar, 211440.00%
31 Dec, 2010-

- institutional shareholders have increased their position in VVOS stock as of 31 Dec 23 compared to 6 in the previous quarter (a -100.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Dec, 23--100.00%
30 Sep, 234-42.86%
30 Jun, 23740.00%
31 Mar, 235-16.67%
31 Dec, 226-25.00%
30 Sep, 22814.29%
30 Jun, 22716.67%
31 Mar, 226-40.00%
31 Dec, 2110233.33%
30 Sep, 21350.00%
30 Jun, 212-33.33%
31 Mar, 213-
31 Dec, 20--

- institutional shareholders have reduced their position in VVOS stock as of 31 Dec 23 compared to 4 in the previous quarter (a -100.00% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Dec, 231-96.15%4,000-99.91%0.33%0.15%--100.00%--100.00%
30 Sep, 2326-13.33%4,475,024-4.63%14.95%4.16%6-45.45%4-42.86%
30 Jun, 2330-3.23%4,692,243-6.39%18.95%4.62%11-15.38%740.00%
31 Mar, 233114.81%5,012,314220.31%20.24%43.77%138.33%5-16.67%
31 Dec, 2227-1,564,827-26.28%6.80%6.80%1250.00%6-25.00%
30 Sep, 22278.00%2,122,576-2.66%10.00%9.48%8-20.00%814.29%
30 Jun, 2225-13.79%2,180,477-12.28%10.27%7.49%10-44.44%716.67%
31 Mar, 2229-2,485,61911.28%11.71%10.18%1863.64%6-40.00%
31 Dec, 2129-34.09%2,233,704-1.32%10.73%9.08%11-62.07%10233.33%
30 Sep, 214457.14%2,263,679-3.56%10.87%8.48%2926.09%350.00%
30 Jun, 212864.71%2,347,130186.00%11.32%55.73%2364.29%2-33.33%
31 Mar, 211770.00%820,68412.44%4.51%25.91%1440.00%3-
31 Dec, 2010-729,879-4.17%-10---

Vivos Therapeutics Insider Shareholders Trades

Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy14,000$0.53$7.42K86,521
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy5,000$0.53$2.65K72,521
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy10,000$0.54$5.40K67,521
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy21$0.50$10.5057,521
Jun 15, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy10,000$0.49$4.90K57,500
Dec 28, 2022Huntsman Ronald Kirkofficer Chief Executive OfficerP-PurchaseBuy20,000$0.50$10.00K47,500

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy14,000$0.53$7.42K86,521
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy5,000$0.53$2.65K72,521
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy10,000$0.54$5.40K67,521
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy21$0.50$10.5057,521
Jun 15, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy10,000$0.49$4.90K57,500
Dec 28, 2022Huntsman Ronald Kirkofficer Chief Executive OfficerP-PurchaseBuy20,000$0.50$10.00K47,500

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jun 28, 2024Huntsman Ronald Kirkdirector, officer Chief Executive OfficerA-AwardBuy20,000$2.38$47.60K49,334
Jun 28, 2024SOKOLOW LEONARD Jdirector-A-AwardBuy4,000$2.38$9.52K7,467
Jun 28, 2024Thompson Matthewdirector-A-AwardBuy4,000$2.38$9.52K7,067
Jun 28, 2024Krammer Anja Bdirector-A-AwardBuy4,000$2.38$9.52K7,067
Jun 28, 2024Green Ralph Eliasdirector-A-AwardBuy4,000$2.38$9.52K7,067
Jun 28, 2024Amman Bradford K.officer Chief Financial OfficerA-AwardBuy15,000$2.38$35.70K31,667
Jun 28, 2024Lindsay Mark F.director-A-AwardBuy4,000$2.38$9.52K7,067
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy14,000$0.53$7.42K86,521
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy5,000$0.53$2.65K72,521
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy10,000$0.54$5.40K67,521
Jun 20, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy21$0.50$10.5057,521
Jun 15, 2023Huntsman Ronald Kirkdirector, officer Chief Executive OfficerP-PurchaseBuy10,000$0.49$4.90K57,500
Dec 28, 2022Krammer Anja Bdirector-A-AwardBuy30,000$0.48$14.40K76,667
Dec 28, 2022SOKOLOW LEONARD Jdirector-A-AwardBuy30,000$0.48$14.40K76,667
Dec 28, 2022Thompson Matthewdirector-A-AwardBuy30,000$0.48$14.40K76,667
Dec 28, 2022Huntsman Ronald Kirkofficer Chief Executive OfficerA-AwardBuy150,000$0.48$72.00K483,334
Dec 28, 2022Huntsman Ronald Kirkofficer Chief Executive OfficerA-AwardBuy333,334$0.48$160.00K333,334
Dec 28, 2022Huntsman Ronald Kirkofficer Chief Executive OfficerP-PurchaseBuy20,000$0.50$10.00K47,500
Dec 28, 2022Lindsay Mark F.director-A-AwardBuy30,000$0.48$14.40K76,667
Dec 28, 2022Amman Bradford K.officer Chief Financial OfficerA-AwardBuy200,000$0.48$96.00K500,001

The last insider buy of VVOS was made by Huntsman Ronald Kirk on Jun 20 2023, buying 14,000 shares at $0.53 per share (worth $7.42K).

Vivos Therapeutics Insider Ownership Trends

All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20235--
Q4 20229--
Q2 20221--
Q1 20222--
Q3 20219--
Q2 20213--
Q1 20212--
Q4 20203837.50%
Q4 20191--
Q4 20181--

5 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Vivos Therapeutics's insiders, as of Q2 2023.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20235--
Q4 20221--
Q2 20221--
Q1 2022---
Q3 20212--
Q2 20212--
Q1 2021---
Q4 20203--
Q4 2019---
Q4 2018---

As of Q2 2023, Insider owners conducted 5 open market buy trades and 0 open market sell trades of Vivos Therapeutics's stocks.

Vivos Therapeutics Peer Ownership

TickerCompany
TLISTalis Biomedical Corporation
RPIDRapid Micro Biosystems, Inc.
TIVCTivic Health Systems, Inc.
NUWENuwellis, Inc.
BBLGBone Biologics Corporation
BJDXBluejay Diagnostics, Inc.
HSCSHeart Test Laboratories, Inc.
NAOVNanoVibronix, Inc.

VVOS Ownership FAQ

Vivos Therapeutics is owned by institutional shareholders (0.33%), insiders (5.93%), and public (93.73%). The largest institutional shareholder of Vivos Therapeutics is RONALD BLUE TRUST, INC. (0% of total shares) and the top mutual fund owner is ROYCE FUND (0.05% of total shares).

Vivos Therapeutics's major institutional shareholders are RONALD BLUE TRUST, INC.. The top five shareholders own together 0% of the company's share outstanding.

As of Dec 2023, there are 1 institutional shareholders of Vivos Therapeutics.

RONALD BLUE TRUST, INC owns 0 shares of Vivos Therapeutics, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).